These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15478075)

  • 21. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of opportunistic DNA viral infections by multiplex PCR among HIV infected individuals receiving care at a tertiary care hospital in South India.
    Sachithanandham J; Ramamurthy M; Kannangai R; Daniel HD; Abraham OC; Rupali P; Pulimood SA; Abraham AM; Sridharan G
    Indian J Med Microbiol; 2009; 27(3):210-6. PubMed ID: 19584500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.
    Kalou M; Sassan-Morokro M; Abouya L; Bile C; Maurice C; Maran M; Tossou O; Roels T; Greenberg AE; Wiktor SZ; Nkengasong JN
    J Med Virol; 2005 Feb; 75(2):202-8. PubMed ID: 15602734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
    Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
    Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
    Cassol E; Page T; Mosam A; Friedland G; Jack C; Lalloo U; Kopetka J; Patterson B; Esterhuizen T; Coovadia HM
    J Infect Dis; 2005 Feb; 191(3):324-32. PubMed ID: 15633090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevalence of tuberculosis and its impact on mortality among HIV infected patients in Chile].
    Villarroel L; Rabagliati R; Balcells ME; Karzulovic L; Pérez C
    Rev Med Chil; 2008 May; 136(5):578-86. PubMed ID: 18769804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of HIV-infected tuberculosis patients in Thailand.
    Mankatittham W; Likanonsakul S; Thawornwan U; Kongsanan P; Kittikraisak W; Burapat C; Akksilp S; Sattayawuthipong W; Srinak C; Nateniyom S; Tasaneeyapan T; Varma JK
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):93-103. PubMed ID: 19323040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals.
    Aichelburg MC; Rieger A; Breitenecker F; Pfistershammer K; Tittes J; Eltz S; Aichelburg AC; Stingl G; Makristathis A; Kohrgruber N
    Clin Infect Dis; 2009 Apr; 48(7):954-62. PubMed ID: 19245343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemiology of HIV-associated tuberculosis in rural Cambodia.
    Cain KP; Kanara N; Laserson KF; Vannarith C; Sameourn K; Samnang K; Qualls ML; Wells CD; Varma JK
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):1008-13. PubMed ID: 17705980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of viral hepatitis and infectious complications among human immunodeficiency virus-infected injection drug users at a referral hospital.
    Liang SH; Lo YC; Lin HH; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2008 Jun; 41(3):200-8. PubMed ID: 18629414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis and HIV co-infections in Jamaican children.
    Geoghagen M; Farr JA; Hambleton I; Pierre R; Christie CD
    West Indian Med J; 2004 Oct; 53(5):339-45. PubMed ID: 15675501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression.
    Collins KR; Quiñones-Mateu ME; Toossi Z; Arts EJ
    AIDS Rev; 2002; 4(3):165-76. PubMed ID: 12416451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.